---
title: "Elevance Health Inc. Faces Securities Fraud Class Action Over Misleading Cost Trend Monitoring and Rate Negotiations"
description: "Elevance Health Inc. is facing a securities fraud class action investigation by the Grabar Law Office. Allegations suggest that company officers misrepresented cost trend monitoring related to Medicai"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/256924472.md"
published_at: "2025-09-11T12:14:33.000Z"
---

# Elevance Health Inc. Faces Securities Fraud Class Action Over Misleading Cost Trend Monitoring and Rate Negotiations

> Elevance Health Inc. is facing a securities fraud class action investigation by the Grabar Law Office. Allegations suggest that company officers misrepresented cost trend monitoring related to Medicaid, failing to account for higher costs from sicker patients. This oversight was not reflected in the 2024 financial guidance, leading to claims of misleading statements about financial prudence. Shareholders who bought shares before April 18, 2024, are urged to contact the law office for potential recovery options.

Philadelphia, Pennsylvania - September 11, 2025 - Elevance Health Inc. (NYSE: ELV) is currently under investigation by the Grabar Law Office for potential regulatory issues linked to securities fraud. The investigation centers on allegations that certain officers of the company misrepresented their monitoring of cost trends related to the Medicaid redetermination process. It is claimed that Elevance’s rate negotiations with states did not adequately account for higher costs associated with sicker patients remaining on Medicaid. This alleged oversight was not reflected in the company’s financial guidance for 2024, leading to accusations that Elevance’s statements regarding their financial prudence were misleading. Shareholders who purchased shares before April 18, 2024, are encouraged to contact Grabar Law Office to explore potential corporate reforms and recovery of funds at no cost. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elevance Health Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 266014) on September 11, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

### Related Stocks

- [ELV.US - Elevance Health](https://longbridge.com/en/quote/ELV.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Elevance Health Inc. Files Initial Statement of Beneficial Ownership for Director Amy W. Schulman | Elevance Health Inc. has filed an initial statement of beneficial ownership (Form 3) with the U.S. Securities and Exchan | [Link](https://longbridge.com/en/news/272602882.md) |
| Elevance Health, Inc. SEC 10-K Report | Elevance Health, Inc. has released its annual Form 10-K report, detailing its financial and operational performance. The | [Link](https://longbridge.com/en/news/275168871.md) |
| Aleen Inc. Insights: What Are AI Agents and How They Fit Into Digital Wellness | Aleen Inc. (CSE: ALEN.U), a digital wellness company, provides an overview of AI agents, which are software systems desi | [Link](https://longbridge.com/en/news/275462510.md) |
| 5 states where $100K a year feels like $100K - and 5 where it shrinks to $45K after hidden costs | 5 States Where $100K a Year Feels Like $100K - and 5 Where It Shrinks to $45K After Hidden Costs | [Link](https://longbridge.com/en/news/275460028.md) |
| Director Avrohom J. Kess Reports Acquisition of Varonis Systems Inc. Common Shares | Avrohom J. Kess, a director at Varonis Systems Inc., has reported the acquisition of common shares in the company. The f | [Link](https://longbridge.com/en/news/275528812.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.